Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

Quick facts

Phase 2 pipeline

• Abiraterone - Usual · Oncology
  Abiraterone is an androgen biosynthesis inhibitor that blocks the production of testosterone in the body.
• Alectinib - Usual · Oncology
  Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor that targets the ALK protein.
• ETOPOSIDE - Usual · Oncology
  Etoposide is a topoisomerase II inhibitor that works by interfering with the enzyme topoisomerase II, which is involved in DNA replication and cell division.
• Raloxifene - Usual
• Topotecan - usual

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair portfolio CI brief
• Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair pipeline updates RSS

Related

• Sector hub: All tracked pharma companies